Managed to get my allocation on application. Very happy with the outcome.
Looking forward to seeing how the Noxopharm plan progresses. Key points for me are:
> NOX66 is a novel formulation of an effective compound - idronoxil
> Broad application across a range of cancers
> Trials in Eastern Europe is lower cost, the process quicker and apparently the ‘quality’ of patients is better since this may be their first treatment instead of last
> GK experienced at Human Trials and bringing drugs to market
All thumbs up for me plus a low enterprise value mean a strong investment opportunity I think. Let’s see if we start getting some good news in 2016 to set us up for a strong 2017
GLTA
Listing today
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
-0.001(1.64%) |
Mkt cap ! $17.53M | |||
| Open | High | Low | Value | Volume |
| 6.2¢ | 6.3¢ | 6.0¢ | $8.932K | 146.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 219003 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.7¢ | 150000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 6.1¢ | 6.1¢ | 6.1¢ | 13508 | ||
| Last updated 14.22pm 08/05/2024 ? | |||||
| NOX (ASX) Chart |